Lawrence Eichenfield

Jun 27, 2024 | dermatologytimes.com | Lawrence Eichenfield

June 27, 2024A dermatology expert reviews findings from a recently presented study on using other atopic dermatitis (AD) treatments within six months of initiating ruxolitinib cream. The expert assesses ruxolitinib's effectiveness and potential role in treatment, highlighting the need for further research on its long-term implications in AD management.

Jun 21, 2024 | dermatologytimes.com | Lawrence Eichenfield

June 20, 2024Lawrence Eichenfield, MD, explores the significant comorbidities and conditions, such as allergic rhinitis, anxiety, and asthma, that intersect with atopic dermatitis (AD), discussing their influence on disease management and treatment response, as well as the observed treatment patterns of patients with this condition before and after the initiation of ruxolitinib therapy.

Jun 13, 2024 | dermatologytimes.com | Lawrence Eichenfield

June 13, 2024An expert in the management of dermatological conditions shares insights on managing atopic dermatitis patients, discussing the real-world effectiveness and physician satisfaction with ruxolitinib cream as a treatment option, as well as its adoption among healthcare providers. Video content above is prompted by the following question(s):How do the study findings align with your own clinical experiences and observations in managing patients with atopic dermatitis (AD)?

Jun 10, 2024 | managedhealthcareexecutive.com | Lawrence Eichenfield

June 10, 2024Lawrence Eichenfield, MD, discusses promising avenues for future research and innovation in the field of atopic dermatitis.

Jun 6, 2024 | dermatologytimes.com | Lawrence Eichenfield

June 6, 2024In this recently presented poster, a dermatology expert draws on clinical experience to reveal why healthcare providers switch treatments for atopic dermatitis (AD). The expert also examines how these reasons vary with disease stage and patient demographics, offering nuanced insights into AD management. In your experience, what are the most commonly cited reasons by healthcare providers for switching treatments in patients with AD?